Advertisement

Introduction to Cancer Prevention

  • David S. AlbertsEmail author
  • Lisa M. Hess
Chapter
  • 417 Downloads

Abstract

The goals of cancer prevention are to reduce the incidence, morbidity, and mortality due to cancer through the identification and elimination of precancerous lesions or the early detection of minimally invasive cancers. Globally, there is a great deal of heterogeneity between countries regarding cancer risk, incidence, and mortality. Prostate cancer is the most frequently diagnosed cancer among men in both North and South America and in Western Europe, whereas lung cancer is the most common among men in Eastern Europe (Torre et al. 2015). Among women, breast cancer is the most frequent diagnosis in North America and Europe, but in China and North Korea lung cancer is more common. While declining incidence and mortality rates have been observed across all cancers in the United States (Siegel et al. 2018), rates are rising in many low- to middle-income countries around the world (Torre et al. 2015).

Keywords

Statistics Incidence Mortality Cancer risk Research Primary prevention Secondary prevention Tertiary prevention Clinical trials 

References

  1. ACS (2008) American Cancer Society Cancer Facts & Figures 2008, Special Section, p 22–42. http://www.cancer.org/acs/groups/content/@nho/documents/document/2008cafffinalsecuredpdf.pdf. Accessed 13 Feb 2013
  2. Alberts DS, Barakat RR et al (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330(15):1029–1035CrossRefGoogle Scholar
  3. Alberts DS, Barakat RR et al (2004) Prevention of gynecologic malignancies. In: Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas G (eds) Gynecologic cancer: controversies in management. El Sevier Ltd, PhiladelphiaGoogle Scholar
  4. Balakrishnan M, George R, Sharma A, Graham DY (2017) Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep 19(8):36CrossRefGoogle Scholar
  5. Biganzoli EM, Cesana BM. Phase IV studies: some insights, clarifications, and issues. Curr Clin Pharmacol. 201813(1):14-20Google Scholar
  6. Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 13(8):790–801CrossRefGoogle Scholar
  7. Bray F, Jemal A, Torre LA, Forman D, Vineis P (2015) Long-term realism and cost-effectiveness: primary prevention in combatting cancer and associated inequalities worldwide. J Natl Cancer Inst 107(12)CrossRefGoogle Scholar
  8. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102CrossRefGoogle Scholar
  9. Burton GW, Ingold KU (1984) Beta-carotene: an unusual type of lipid antioxidant. Science 224(4649):569–573CrossRefGoogle Scholar
  10. Dieleman J, Campbell M, Chapin A, Eldrenkamp E, Fan VY, Haakenstad A, Kates J, Liu Y, Matyasz T, Micah A, Reynolds A (2017) Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet 389(10083):1981–2004CrossRefGoogle Scholar
  11. Fisher B, Costantino JP et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388CrossRefGoogle Scholar
  12. Freedman AN, Graubard BI, Rao SR et al (2003) Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95(7):526–532CrossRefGoogle Scholar
  13. George SM, Irwin ML, Smith AW, Neuhouser ML et al (2011) Postdiagnosis diet quality, the combination of diet quality and recreational physical activity, and prognosis after early-stage breast cancer. Cancer Causes Control 22(4):589–598CrossRefGoogle Scholar
  14. Gupta S, Kumar P, Das BC (2018) HPV: molecular pathways and targets. Curr Probl Cancer 42:161–174CrossRefGoogle Scholar
  15. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70.  https://doi.org/10.1016/S0092-8674(00)81683-9CrossRefPubMedPubMedCentralGoogle Scholar
  16. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefGoogle Scholar
  17. IOM (Institute of Medicine) (2002) Care without coverage: too little, too late. National Academy Press, Washington, DCGoogle Scholar
  18. Jemal A, Ward E, Thun M (2010) Declining death rates reflect progress against cancer. PLoS One 15(3):e9584CrossRefGoogle Scholar
  19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefGoogle Scholar
  20. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T, Peto R (2013) 21st century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368:341–350CrossRefGoogle Scholar
  21. Keehan SP, Stone DA, Poisal JA, Cuckler GA, Sisko AM, Smith SD, Madison AJ, Wolfe CJ, Lizonitz JM (2017) National health expenditure projections, 2016–25: price increases, aging push sector to 20 percent of economy. Health Aff 36(3):553–563CrossRefGoogle Scholar
  22. Mackay J, Jemal A, Lee N et al (2006) The cancer atlas. The American Cancer Society, AtlantaGoogle Scholar
  23. Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, Gentry-Maharaj A, Kalsi JK, Singh N, Amso NN, Cruickshank D (2017) The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Br J Cancer 117(5):619CrossRefGoogle Scholar
  24. Menter DG, Schilsky RL, DuBois RN (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384–1390CrossRefGoogle Scholar
  25. Morrison AH, Byrne KT, Vonderheide RH (2018) Immunotherapy and prevention of pancreatic cancer. Trends Cancer 4:418–428CrossRefGoogle Scholar
  26. National Center for Health Statistics (2017) US. Health, United States, 2016: with chartbook on long-term trends in health. National Center for Health Statistics (US), HyattsvilleGoogle Scholar
  27. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). 2018SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. Bethesda., https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018
  28. Nørgaard M, Ehrenstein V, Vandenbroucke JP (2017) Confounding in observational studies based on large health care databases: problems and potential solutions–a primer for the clinician. Clin Epidemiol 9:185CrossRefGoogle Scholar
  29. O’Shaughnessy JA, Kelloff GJ et al (2002) Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8(2):314–346PubMedGoogle Scholar
  30. Omenn GS, Goodman GE et al (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88(21):1550–1559CrossRefGoogle Scholar
  31. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30CrossRefGoogle Scholar
  32. Sipp D, Frazer IH, Rasko JE (2018) No Vacillation on HPV Vaccination. Cell 172(6):1163–1167CrossRefGoogle Scholar
  33. Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T (2017) Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk–combined results from two screening trials. Clin Cancer Res 23(14):3628–3637CrossRefGoogle Scholar
  34. Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36(7 PT 2):2699–2702PubMedGoogle Scholar
  35. Stevens GA, Singh GM, Lu Y et al (2012) National, regional and global trends in adult overweight and obesity prevalences. Popul Health Metrics 10:22.  https://doi.org/10.1186/1478-7954-10-22CrossRefGoogle Scholar
  36. Stewart B, Wild CP (eds) (2014) World cancer report 2014. IARC, WHO, Lyon. Accessed 2017 Oct 24.Google Scholar
  37. Streeter AJ, Lin NX, Crathorne L, Haasova M, Hyde C, Melzer D, Henley WE (2017) Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review. J Clin Epidemiol 87:23–34CrossRefGoogle Scholar
  38. Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24(2):96–102CrossRefGoogle Scholar
  39. Thomson CA, Crane TE, Miller A, Garcia DO, Basen-Engquist K, Alberts DS (2016) A randomized trial of diet and physical activity in women treated for stage II–IV ovarian cancer: rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): an NRG Oncology/Gynecologic Oncology Group (GOG-225) Study. Contemp Clin Trial 49:181–189CrossRefGoogle Scholar
  40. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K (2009) A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 62(5):464–475CrossRefGoogle Scholar
  41. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM (2010) The global burden of cancer: priorities for prevention. Carcinogenesis 31(1):100–110CrossRefGoogle Scholar
  42. Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 25(1):16–27CrossRefGoogle Scholar
  43. Vogel VG, Constantino VP et al (2006) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295(23):2727–2741CrossRefGoogle Scholar
  44. Walker TY, Elam-Evans LD, Singleton JA et al (2017) National, Regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2016. MMWR Morb Mortal Wkly Rep 66:874–882.  https://doi.org/10.15585/mmwr.mm6633a2CrossRefGoogle Scholar
  45. Wattenberg LW (1993) Prevention–therapy–basic science and the resolution of the cancer problem. Cancer Res 53(24):5890–5896PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.College of MedicineUniversity of Arizona Cancer CenterTucsonUSA
  2. 2.Department of Obstetrics and GynecologySchools of Medicine and Public Health, Indiana UniversityIndianapolisUSA

Personalised recommendations